Houston medtech accelerator announces inaugural cohort

future of health care

Five companies have been selected for a brand new accelerator program in Houston. Image via Getty Images

A Houston medical technology organization has announced the inaugural cohort of a new early-stage accelerator.

M1 MedTech, launched this year by Houston-based Proxima Clinical Research, announced its Fall 2022 cohort.

“This initial cohort launches M1 MedTech with an interactive 14-week agenda covering the basics every emerging MedTech business needs to progress from a startup to an established solution in their market,” says Sean Bittner, director of programs at M1 MedTech, in a news release.

The accelerator will equip early-stage startups with storytelling, business plan support, investor connections, FDA guidance, research, and more through one-on-one consultations, workships, and in-kind services.

The first cohort includes five startups, per the release from the company:

  1. Linovasc. Providing a long overdue major update to balloon angioplasty devices in over 50 years, the Linovasc solution offers a safer branch occlusion and aortic stent dilatation using a toroidal balloon that expands the aorta uniformly without the ischemia caused by current treatments. The company is founded by Bruce Addis.
  2. Grapheton. Founded by Sam Kassegne and Bao Nguyen, Grapheton's patented carbon materials work with electrically active devices to improve the longevity and outcome of bioelectric implants in the body. Terry Lingren serves as the CEO of the startup.
    • Rhythio Medical. Founded by Kunal Shah and Savannah Esteve, Rhythio is the first preventative approach to heart arrhythmias.The chief medical officer is Dr. Mehdi Razavi.
      • PONS Technology. An AI cognitive functioning ultrasound device attempting to change the way ultrasound is done, PONS is founded by CEO: Soner Haci and CTO: Ilker Hacihaliloglu.
        • Vivifi Medical. Founded by CEO Tushar Sharma, Vivifi is the first suture-less laparoscopic technology that connects vessels to improve male infertility and benign prostatic hyperplasia. The company's senior R&D engineer is Frida Montoya.

          The program includes support from sponsors and experts from: Proxima Clinical Research, Greenlight Guru, Medrio, Galen Data, Merge Medical Device Studio, Venn Negotiation, Engagement PR & Marketing, Aleberry Creative, and others.

          “This is an amazing opportunity for emerging founders to learn the progression of pipelining their ideas through the FDA and absorb the critical strategies for success early in their business development,” says Isabella Schmitt, principal at M1 MedTech and director of regulatory affairs at Proxima CRO, in the release.

          Proxima Clinical Research has its New Year's resolution and is ready to start working hands on with health tech startups. Graphic via proximacro.com

          Houston organization plans to launch health tech accelerator in 2022

          ready to grow

          A contract research organization based in Houston has announced its new accelerator program aimed at helping startups quickly grow their health tech businesses.

          Proxima Clinical Research released details of M1 MedTech, which expects to launch early next year. The CRO has raised funds to launch and invest in members of the inaugural cohort.

          “Our goal is to move these companies substantially forward in a short amount of time,” says Kevin Coker, CEO of Proxima, in a news release. “Proxima is in a unique position to leverage our experienced team of regulatory, quality, and clinical experts. We won’t be working at arm’s length from these companies. We will be a big part of what they do every day.”

          The program will focus on a small group of companies and the Proxima team will provide hands-on support, including instruction, workshops, and one-on-one mentoring.

          “This will be a unique experience for all parties involved, as Proxima is also a young, yet established, company that is now creating a program to assist companies at an earlier stage,” says Larry Lawson, co-founder of Proxima, in the release. “Our experience in the CRO realm and ability to provide coaching in clinical, regulatory, quality, and go-to-market strategies will only strengthen M1 MedTech’s ability to support the success of emerging companies and provide more life-saving technology to the public.”

          Kevin Coker and Larry Lawson co-founded Proxima in 2017. Photos courtesy

          The accelerator will target Class II and III medical devices for its initial cohort. In the future, Proxima plans to expand to include an even more extensive incubator focused solely on Class III devices, according to the release.

          “M1 will be a place where startups can go to receive concrete resources to further their development. The participant success is our sole focus, and the ultimate goal is to have a substantial impact on the ideation-to-market process for Class II and Class III medical devices,” says Isabella Schmitt, director of regulatory affairs at Proxima and a principal at M1, in the release. “Proxima’s specific expertise alongside our M1 partners will provide resources for all key areas of a medical device entrepreneur’s journey to market and beyond.”

          The M1 MedTech applications will open online in the spring.

          “We don’t view M1 as competitive to other accelerators, rather we believe it will offer a different experience. Our team will strive to create a personalized program where companies have a dedicated touch point throughout the process,” says Sean Bittner, director of programs at M1 MedTech, in the release. “We will also provide specific, tailored connections and resources vetted by our team through professional partnerships, not just a general list of industry contacts.”

          Ad Placement 300x100
          Ad Placement 300x600

          CultureMap Emails are Awesome

          Property Showcase

          Rice University opens biotech venture studio in TMC

          rapidly scaling

          In its mission to amplify and advance biotech innovation, Rice University has announced its latest initiative — a new lab focused on bringing life-saving medical technologies to commercialization.

          Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

          Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

          “This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems.

          "Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum," he continues. "We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

          Strategically located in TMC, RBL will collaborate with medical leaders, investors, corporations, and other players both in the same building and on the greater TMC campus.

          “Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the world-class translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” William McKeon, president and CEO of the TMC, says in the release. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

          RBL is Rice's latest effort to bridge the gap between academia and biotech innovation, an effort led by Paul Cherukuri, Rice’s chief innovation officer, who reportedly spearheaded development of the new initiative.

          “RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri adds. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

          Since the Rice Biotech Launch Pad was established, Motif Neurotech closed its series A round with an oversubscribed $18.75 million, the hub secured a $34.9 million grant, and a “living pharmacy” founded at the Launch Pad received industry validation.

          “RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh says. “Our goal is to rapidly bring Rice’s pioneering research into the clinic, delivering life-saving solutions to patients around the world.”

          Houston hospital named among smartest in the nation

          hi, tech

          Houston hospitals are chock-full of smart people. But they’re also equipped with lots of “smart” technology. In fact, five local hospitals appear on Newsweek’s new list of the world’s best “smart” hospitals.

          To compile the list, Newsweek teamed up with data provider Statista to rank the world’s top 330 hospitals for the use of smart technology. The ranking factors were electronic functionality, telemedicine, digital imaging, artificial intelligence (AI), and robotics.

          The highest-ranked Houston hospital is the University of Texas MD Anderson Cancer Center, appearing at No. 6. The hospital was recognized for advancements in electronic functionality, AI and robotics.

          “MD Anderson has a significant opportunity and a responsibility to our many stakeholders to create a digital ecosystem that promotes collaboration and advances scientific discovery to enhance patient outcomes,” David Jaffray, the cancer center’s chief technology and digital officer, said in a 2021 news release.

          “Through our ongoing focus on enabling the use of new technologies to place quantitative data in context for our researchers,” Jaffray added, “we foster cutting-edge oncology data science to inform our cancer discovery research and to accelerate translation of our research findings into benefits for cancer patients.”

          Ahead of MD Anderson on the list are:

          1. Mayo Clinic in Rochester, Minnesota.
          2. Cleveland Clinic in Cleveland.
          3. Massachusetts General Hospital in Boston.
          4. Johns Hopkins Hospital in Baltimore.
          5. Mount Sinai Hospital in New York City.

          Other Houston hospitals on the list are:

          • Houston Methodist Hospital, No. 11.
          • Baylor St. Luke’s Medical Center, No. 105.
          • Texas Children’s Hospital, No. 197.
          • Memorial Hermann-Texas Medical Center, No. 266.

          Expert: How to best repurpose Houston’s infrastructure for a clean energy future

          guest column

          Houston, often dubbed the “Energy Capital of the World,” is at a pivotal moment in its history. Known for its vast oil and gas reserves, the city is now embracing a new role as a leader in the clean energy transition. This shift is not just about adopting new technologies but also about creatively repurposing existing infrastructure to support sustainable energy solutions.

          Houston’s offshore oil wells, many of which are old or abandoned, present a significant opportunity for carbon capture. By repurposing these wells, we can sequester carbon dioxide, reducing greenhouse gas emissions and mitigating climate change. This approach not only utilizes existing infrastructure but also provides a cost-effective solution for carbon management. According to the Greater Houston Partnership, initiatives like these are crucial as Houston aims to lower its climate-changing greenhouse gas emissions. Exxon estimates that just their proposed CCS hub could capture and store 50 million metric tons of CO2 annually by 2030 and 100 million metric tons by 2040.

          The proximity of abandoned offshore platforms to the coast makes them ideal candidates for renewable energy substations. These platforms can be transformed into hubs for wind, solar or tidal energy, facilitating the integration of renewable energy into the grid. This repurposing not only maximizes the use of existing structures but also minimizes environmental disruption.

          Decommissioned pipelines, which are already in place, offer a ready-made solution for routing renewable energy cables. By using these existing rights of way, Houston can avoid disturbing additional seafloor and reduce the environmental impact of new cable installations. This strategy ensures a smoother transition to renewable energy infrastructure. The U.S. Energy Information Administration notes that Texas, including Houston, leads the nation in wind-generated electricity, highlighting the potential for further renewable energy development.

          Onshore oil and gas facilities in Houston also hold potential for clean energy repurposing. Wells that were drilled but never used for oil or gas can be adapted for geological thermal energy storage. This process involves storing excess renewable energy in the form of heat, which can be retrieved when needed, providing a reliable and sustainable energy source. This innovative use of existing wells aligns with Houston’s broader energy transition strategy, which aims to leverage the city’s industrial expertise for a low-carbon future.

          Once the land has been remediated, old and abandoned oil fields can be converted into solar farms. This transformation not only provides a new use for previously contaminated land but also contributes to the generation of clean, renewable energy. Solar farms on these sites can help meet Houston’s energy needs while supporting environmental restoration. The Environmental Protection Agency in recent years recognized Houston as the top city in the U.S. for green energy usage, with annual green power usage topping 1 billion kilowatt-hours in 2021.

          Houston’s journey towards a clean energy future is a testament to the power of innovation and adaptability. By repurposing existing infrastructure, we can create a sustainable energy landscape that honors the city’s industrial past while paving the way for a greener tomorrow. These strategies highlight the potential for Houston to lead in the clean energy transition, setting an example for cities worldwide.

          ———

          Tershara Mathews is the national offshore wind lead at WSP.

          This article originally ran on EnergyCapital.


          View All Listings